Non-keratinizing sinonasal squamous cell carcinoma

Summary

Non-keratinizing sinonasal squamous cell carcinoma (MONDO:0002831) is a cancer and 8 clinical trials. Top therapeutic interventions include cisplatin, atezolizumab, and cetuximab. A subtype of nasal cavity and paranasal sinus squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-keratinizing sinonasal squamous cell carcinoma
Mondo ID	MONDO:0002831
DOID	DOID:4003
NCIT	C54287
UMLS	C0334270
MedGen	83119
GARD	0023258
Is cancer (heuristic)	yes

Also known as: non-keratinizing sinonasal squamous cell carcinoma · sinonasal squamous cell carcinoma

Data availability: 6 cell lines.

Disease family

This is a subtype of nasal cavity and paranasal sinus squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › nasal cavity and paranasal sinus squamous cell carcinoma › non-keratinizing sinonasal squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	4
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00588770	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05063552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT07209189	PHASE2	RECRUITING	Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT07281417	PHASE2	RECRUITING	Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
NCT02567422	PHASE1	ACTIVE_NOT_RECRUITING	Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT03803774	PHASE1	ACTIVE_NOT_RECRUITING	Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
NCT05172245	PHASE1	RECRUITING	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT06868433	PHASE1	RECRUITING	TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	5
ATEZOLIZUMAB	4	1
CETUXIMAB	4	1
IPATASERTIB	3	1
BERZOSERTIB	2	1
BIRINAPANT	2	1
CHEMBL5412235	0	1